Stocktoria
Centessa Pharmaceuticals plc CNTA
Centessa Pharmaceuticals plc (CNTA) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $15.0M at a -1316.9% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Manufacturing · percentile among 1829 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.473 |
| Retained earnings / assets | -1.725 |
| EBIT / assets | -0.302 |
| Equity / liabilities | 3.28 |
Detailed pages
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | 4/9 | -1.11 | — | — |
| NEUP | Neuphoria Therapeutics Inc. | 4/9 | -16.04 | — | — |
| IRD | Opus Genetics, Inc. | 3/9 | -11.42 | — | +29.1% |
| ABUS | Arbutus Biopharma Corp | 3/9 | — | — | — |
| QURE | uniQure N.V. | 4/9 | -1.71 | — | -40.6% |
| PYXS | Pyxis Oncology, Inc. | 2/9 | -16.86 | — | -14.2% |
| ZYBT | Zhengye Biotechnology Holding Ltd | 4/9 | 1.49 | — | -91.1% |
FAQ
Is CNTA financially healthy?
Centessa Pharmaceuticals plc's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CNTA pay a dividend?
No, Centessa Pharmaceuticals plc does not currently pay a dividend.
How profitable is CNTA?
In FY2025, Centessa Pharmaceuticals plc had a net margin of -1316.9% and a return on equity of -37.5%.
Source: SEC EDGAR filings · CIK 0001847903 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.